FR2649120B1 - New strain and mutants of filamentous fungi, recombinant protein production process using said strain, and strains and proteins obtained according to such process - Google Patents

New strain and mutants of filamentous fungi, recombinant protein production process using said strain, and strains and proteins obtained according to such process

Info

Publication number
FR2649120B1
FR2649120B1 FR8908838A FR8908838A FR2649120B1 FR 2649120 B1 FR2649120 B1 FR 2649120B1 FR 8908838 A FR8908838 A FR 8908838A FR 8908838 A FR8908838 A FR 8908838A FR 2649120 B1 FR2649120 B1 FR 2649120B1
Authority
FR
France
Prior art keywords
strain
process
mutants
strains
obtained according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR8908838A
Other languages
French (fr)
Other versions
FR2649120A1 (en
Inventor
Calmels Thierry
Durand Henri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cayla
Original Assignee
Cayla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cayla filed Critical Cayla
Priority to FR8908838A priority Critical patent/FR2649120B1/en
Publication of FR2649120A1 publication Critical patent/FR2649120A1/en
Application granted granted Critical
Publication of FR2649120B1 publication Critical patent/FR2649120B1/en
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RPROCESSES USING MICROORGANISMS
    • C12R1/00Processes using microorganisms
    • C12R1/645Processes using microorganisms using fungi
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2451Glucanases acting on alpha-1,6-glucosidic bonds
    • C12N9/2457Pullulanase (3.2.1.41)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01041Pullulanase (3.2.1.41)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
FR8908838A 1989-06-30 1989-06-30 New strain and mutants of filamentous fungi, recombinant protein production process using said strain, and strains and proteins obtained according to such process Expired - Lifetime FR2649120B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR8908838A FR2649120B1 (en) 1989-06-30 1989-06-30 New strain and mutants of filamentous fungi, recombinant protein production process using said strain, and strains and proteins obtained according to such process

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR8908838A FR2649120B1 (en) 1989-06-30 1989-06-30 New strain and mutants of filamentous fungi, recombinant protein production process using said strain, and strains and proteins obtained according to such process
EP19900910778 EP0433431A1 (en) 1989-06-30 1990-06-28 New strain with filamentous fungi mutants, process for the production of recombinant proteins using said strain, and strains and proteins produced by said process
PCT/FR1990/000479 WO1991000357A1 (en) 1989-06-30 1990-06-28 New strain with filamentous fungi mutants, process for the production of recombinant proteins using said strain, and strains and proteins produced by said process

Publications (2)

Publication Number Publication Date
FR2649120A1 FR2649120A1 (en) 1991-01-04
FR2649120B1 true FR2649120B1 (en) 1994-01-28

Family

ID=9383358

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8908838A Expired - Lifetime FR2649120B1 (en) 1989-06-30 1989-06-30 New strain and mutants of filamentous fungi, recombinant protein production process using said strain, and strains and proteins obtained according to such process

Country Status (3)

Country Link
EP (1) EP0433431A1 (en)
FR (1) FR2649120B1 (en)
WO (1) WO1991000357A1 (en)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0643772T3 (en) 1992-06-03 1998-02-02 Genentech Inc Glycosylation variants of tissue plasminogen activator with improved therapeutic properties
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
DE69628652D1 (en) 1995-09-08 2003-07-17 Genentech Inc Vegf-related protein
AT307887T (en) 1996-01-08 2005-11-15 Genentech Inc Ob-receptor and ligand
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
PT1007546E (en) 1997-08-27 2009-04-24 Childrens Hosp & Res Ct Oak Molecular mimetics of meningococcal b epitopes
EP2075253A1 (en) 2000-06-23 2009-07-01 Genentech, Inc. Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DK1029046T3 (en) 1997-10-29 2009-02-02 Genentech Inc WNT-1-inducible genes
US6387657B1 (en) 1997-10-29 2002-05-14 Genentech, Inc. WISP polypeptides and nucleic acids encoding same
EP1484338B1 (en) 1998-12-22 2007-02-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP2333069A3 (en) 1998-05-15 2011-09-14 Genentech, Inc. Therapeutic uses of IL-17 homologous polypeptides
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP1956030B1 (en) 1999-06-15 2009-11-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
AU1316200A (en) 1998-10-15 2000-05-01 Chiron Corporation Metastatic breast and colon cancer regulated genes
EP1669371A3 (en) 1999-12-01 2006-06-21 Genentech, Inc. Composition and methods for the diagnosis of tumours
EP2308974A3 (en) 1999-10-14 2011-08-10 Clontech Laboratories Inc. Anthozoa derived chromo/fluoroproteins and methods for using the same
DK1141331T3 (en) 1998-12-16 2009-01-05 Novartis Vaccines & Diagnostic Human cyclin-dependent kinase (hPNQALRE)
DK1897947T3 (en) 1999-12-23 2012-04-10 Genentech Inc IL-17-homologous polypeptides and therapeutic uses thereof
DE60136281D1 (en) 2000-08-24 2008-12-04 Genentech Inc Method to inhibiting IL-22 induced PAP1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AT402258T (en) 2000-01-10 2008-08-15 Novartis Vaccines & Diagnostic Genes differentially experimiert in brudtkrebs
ES2323220T3 (en) 2000-01-13 2009-07-09 Genentech, Inc. stra6 human polypeptides.
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
CA2451239A1 (en) 2001-06-20 2003-01-03 Genentech, Inc. Antibodies against tumor-associated antigenic taget (tat) polypeptides
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
JP4361791B2 (en) 2001-08-29 2009-11-11 ジェネンテック・インコーポレーテッドGenentech,Inc. Bv8 nucleic acids and polypeptides having mitogenic activity
EP2143438B1 (en) 2001-09-18 2011-07-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumors
AT439368T (en) 2001-12-19 2009-08-15 Univ Chicago Quick Ripening fluorescent proteins and methods for their application
KR100623128B1 (en) 2002-01-02 2006-09-14 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
JP2005535290A (en) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッドGenentech,Inc. Compositions and methods for the treatment of immune-related diseases
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
MXPA04010092A (en) 2002-04-16 2004-12-13 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor.
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
EP1553912A4 (en) 2002-06-07 2007-08-08 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
JP2006517384A (en) 2002-07-08 2006-07-27 ジェネンテック・インコーポレーテッドGenentech,Inc. Compositions and methods for the treatment of immune-related diseases
EP2085096A3 (en) 2002-09-11 2009-08-12 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US20060199181A1 (en) 2002-09-11 2006-09-07 Genentch, Inc. Compositions and methods for the treatment of immune related diseases
EP1578364A4 (en) 2002-09-16 2011-06-08 Genentech Inc Compositions and methods for the treatmentof immune related diseases
US20070042945A1 (en) 2002-09-25 2007-02-22 Genentech, Inc. Nouvelles compositions et methods de traitement du psoriasis
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2503748A1 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
EP1572116A4 (en) 2002-11-26 2007-12-12 Genentech Inc Compositions and methods for the treatment of immune related diseases
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
KR101294959B1 (en) 2003-03-12 2013-08-09 제넨테크, 인크. Use of bv8 and/or eg-vegf to promote hematopoiesis
LT2335725T (en) 2003-04-04 2017-01-25 Genentech, Inc. High concentration antibody and protein formulations
BRPI0411132B1 (en) 2003-06-12 2016-12-13 Lilly Co Eli Heterologous fusion protein and its uses
EP2784084B1 (en) 2003-07-08 2019-07-24 Genentech, Inc. Antagonist antibodies to IL-17A/F heterologous polypeptides
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DE602004024921D1 (en) 2003-11-17 2010-02-11 Genentech Inc Compositions and methods for the treatment of tumors of hematopoietic origin
GB2429207A (en) 2004-02-02 2007-02-21 Ambrx Inc Modified human interferon polypeptides and their uses
WO2005093064A1 (en) 2004-03-29 2005-10-06 Galpharma Co., Ltd. Novel galectin 9 modification protein and use thereof
EP1732944B1 (en) 2004-04-07 2012-09-05 The University of Chicago Monomeric red fluorescent proteins
JP2008503217A (en) 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド New antigen-binding polypeptides and their use
EP1836314B1 (en) 2004-12-22 2012-01-25 Ambrx, Inc. Modified human growth hormone
JP5425398B2 (en) 2004-12-22 2014-02-26 アンブレツクス・インコーポレイテツド Compositions comprising unnatural amino acids and polypeptides, methods relating to unnatural amino acids and polypeptides, and uses of unnatural amino acids and polypeptides
CA2602175C (en) 2005-03-21 2012-11-27 Applera Corporation Alpha ketoamide compounds as cysteine protease inhibitors
JP2008544746A (en) 2005-05-12 2008-12-11 ザイモジェネティクス, インコーポレイテッド Compositions and methods for modulating the immune response
EP2186402A1 (en) 2005-06-06 2010-05-19 Genentech, Inc. Knock-out animal models for novel genes and methods of use
ZA200800970B (en) 2005-08-15 2009-10-28 Genentech Inc Gene disruptions, compositions and methods relating thereto
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
EP1951890A4 (en) 2005-11-16 2009-06-24 Ambrx Inc Methods and compositions comprising non-natural amino acids
CA2630432A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
ZA200807714B (en) 2006-02-17 2010-01-27 Genentech Inc Gene disruptions, compositions and methods relating thereto
EP2389947A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
WO2007126455A2 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
WO2008036437A2 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2027291A2 (en) 2006-04-27 2009-02-25 Pikamab, Inc. Methods and compositions for antibody therapy
WO2007134327A2 (en) 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
EP2044111B1 (en) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting complement factor h for treatment of diseases
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US20080254512A1 (en) 2006-11-02 2008-10-16 Capon Daniel J Hybrid immunoglobulins with moving parts
CN101663407B (en) 2007-02-22 2017-08-08 健泰科生物技术公司 A method for detecting inflammatory bowel disease
ES2385114T3 (en) 2007-03-30 2012-07-18 Ambrx, Inc. FGF-21 modified and their uses
EP2188302B1 (en) 2007-07-09 2017-11-01 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US9845355B2 (en) 2007-07-16 2017-12-19 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
PT2247620T (en) 2008-01-31 2016-08-23 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
AT543835T (en) 2007-07-16 2012-02-15 Genentech Inc Anti-CD79b-antibody and immunoconjugates and application procedures
EA201000343A1 (en) 2007-10-04 2011-10-31 Займодженетикс, Инк. MEMBER OF THE FAMILY B7, zB7H6 AND RELATED COMPOSITIONS AND METHODS
WO2009059305A2 (en) 2007-11-01 2009-05-07 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
US8003325B2 (en) 2007-11-30 2011-08-23 Mayo Foundation For Medical Education And Research Polymorphisms of the BLyS gene and use in diagnostic methods
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
CN102046656A (en) 2008-03-28 2011-05-04 航道生物技术有限责任公司 Neutralizing molecules to viral antigens
AU2009233708B2 (en) 2008-04-09 2015-06-04 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
UA103774C2 (en) 2008-07-23 2013-11-25 Амбркс, Інк. Modified bovine g-csf polypeptides and their uses
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
CN102224238B (en) 2008-09-26 2015-06-10 Ambrx公司 Non-natural amino acid replication-dependent microorganisms and vaccines
NZ592250A (en) 2008-09-26 2012-11-30 Lilly Co Eli Modified animal erythropoietin polypeptides and their uses
CA2764108A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
JP5843357B2 (en) 2009-02-03 2016-01-13 アムニクス オペレーティング インコーポレイテッド Extended recombinant polypeptide and composition comprising extended recombinant polypeptide
EP2440241B1 (en) 2009-06-08 2017-08-09 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP2414399A1 (en) 2009-04-01 2012-02-08 F.Hoffmann-La Roche Ag Anti-fcrh5 antibodies and immunoconjugates and methods of use
JP6016636B2 (en) 2009-10-15 2016-10-26 ジェネンテック, インコーポレイテッド Chimeric fibroblast growth factor with altered receptor specificity
JP5819308B2 (en) 2009-10-22 2015-11-24 ジェネンテック, インコーポレイテッド Methods and compositions for modulating macrophage stimulating protein hepsin activation
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
KR20120103587A (en) 2009-11-12 2012-09-19 제넨테크, 인크. A method of promoting dendritic spine density
SG10201408599QA (en) 2009-11-30 2015-02-27 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
CN104017063A (en) 2009-12-21 2014-09-03 Ambrx公司 Modified porcine somatotropin polypeptides and their uses
MX2012009215A (en) 2010-02-23 2012-11-23 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor.
CA2793544A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP5746761B2 (en) 2010-06-25 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and pharmaceutical compositions for the treatment of respiratory tract infections
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MY162837A (en) 2010-08-17 2017-07-31 Ambrx Inc Modified relaxin polypeptides and their uses
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术(上海)有限公司 Application of interleukin-22 in curing virus hepatitis
JP2014506115A (en) 2010-09-15 2014-03-13 アリグナ テクノロジーズ,インク. Bioproduction of aromatic chemicals from lignin-derived compounds
US20140199682A1 (en) 2010-11-17 2014-07-17 Sea Lane Biotechnologies, Llc Influenza neutralizing agents
US9550818B2 (en) 2012-04-27 2017-01-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for use of vascular endothelial growth factor antagonists
WO2014144911A2 (en) 2013-03-15 2014-09-18 Capon Daniel J Hybrid immunoglobulin containing non-peptidyl linkage
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
JP2017537612A (en) 2014-10-24 2017-12-21 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Modified FGF-21 polypeptides and uses thereof
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE448386B (en) * 1978-10-18 1987-02-16 Sandoz Ag New cyclosporin derivatives, process for the production tell of them as well pharmaceutical composition containing spirit them
FR2569723B1 (en) * 1984-08-31 1986-09-19 Centre Nat Rech Scient Application of antibiotics of the family phleomycines way of selection agent in the field of genetic engineering
DE3650202T3 (en) * 1985-08-29 2004-06-03 Genencor International, Inc., South San Francisco Expression of heterologous polypeptides in filamentous fungi, methods for their production and vectors for their production.
GB8610600D0 (en) * 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma

Also Published As

Publication number Publication date
WO1991000357A1 (en) 1991-01-10
FR2649120A1 (en) 1991-01-04
EP0433431A1 (en) 1991-06-26

Similar Documents

Publication Publication Date Title
NO177701B (en) A process for the preparation of therapeutically active hydroxamic kollagenaseinhibitorforbindelser and to intermediates for use in the method
FR2603575B1 (en) glass product reinforces chemically and method to produce
NO177700B (en) A process for the preparation of therapeutically active hydroxamic kollagenaseinhibitorforbindelser and to intermediates for use in the method
DE69227116T2 (en) Highly stable recombinant yeasts for the production of recombinant proteins
FI95573B (en) Process for the preparation of therapeutically useful pyrrolidine
KR880011341A (en) Recombinant Avi Fox biruseu
KR870011252A (en) New methods of production of hyaluronic acid and cosmetics containing hyaluronic acid bacteria strains, and to produce them
NO160364B (en) Novel intermediate and process for preparation thereof
MA22889A1 (en) new products Preparation Method
FI870113A (en) Process for the preparation of new -2-pyrimidinamine therapeutically useful 4,5,6-substioitujenN- (substituted-phenyl)
MX204417A (en) Method for preparing resin, transparent and resistant to cracking or copolymers cracking and product obtained
IT1199144B (en) Textile for linings with proprieta'anisotrope and process for its production
DE69032743T2 (en) Production of fusion proteins
DE69332030D1 (en) Production of heterologous proteins in filamentous fungi
FI890282A (en) Process for the preparation of therapeutically useful 23,24-didehydro-25-hydroksikalsiferolijohdannaisten
FR2550726B1 (en) ophthalmic lenses resistant to abrasion, antistatic and / or anti REFLECTING and method for making
FI91072C (en) Process for the preparation of therapeutically active hetero-cyclic peptides and their intermediates useful in the preparation of
FI881900A (en) A process for therapeutically useful for the preparation of substituted and imidatsolyylialkyylipiperatsiini- -diatsepiinijohdannaisten
FI935665A (en) Dairy product and process for its preparation
FI875413A0 (en) Process for the preparation of novel therapeutically useful spiro-substituted glutaramide
DE68922932D1 (en) High expression of proteins in yeast.
AT214100T (en) Production of recombinant proteins in a rinderadenovirus-expression vector system
DE69232914D1 (en) Topical preparation containing a suspension of solid lipid particles
FI95147C (en) Process for the preparation of the sugar product and the product produced by the method
FR2568164B1 (en) product production process decorative from fragments or pieces of wood and products obtained